KalshiKullanılabilirliği kontrol etKYC gerekliDoğrulanmış sonuçlanma verisiİyi kalibreSeçili emir defteri orta fiyatı
Before Jul 1, 2027 · —
Seçili emir defteri yükleniyor…
—
Kayıtlı fiyat
Before Jul 1, 2027 89.5%4 seçenek arasında lider
Before Jul 1, 2027 89.5%Piyasa kalitesi
40 / 100
Düşük kalite24s Hacim
₺1,2 B
Açık pozisyon
$6 B
Orta açık pozisyonAlış / Satış
— / —
Before Jul 1, 2027Spread
—
Piyasa verileri
39 dakika önce güncellendi
14 May 26 02:00 UTC1 Oca 27 15:00 UTC
Grafik ve değişimler, seçili canlı emir defterini değil kayıtlı geçmiş olasılıkları gösterir.
Trendler
Seçili satır: emir defteri orta fiyatı. Diğer satırlar: normalleştirilmiş olabilen kayıtlı referanslar; 24 saatlik değişimler kayıtlı geçmişi kullanır.
Before Oct 1, 2026Kaybetti
İşlem platformu koşulları
Kaynak: Kalshi
Bu koşullar yalnızca bilgi amaçlıdır; CoinRithm deneme işlemlerinde kendi kurallarını uygular.
- Erken kapanış:
- Evet
- Sonuçlandırma süresi:
- 30m (bilgi amaçlı)
Piyasa derinliği · Before Jul 1, 2027
Seçili emir defteri yükleniyor…
—
İlgili Piyasalar
Bağlam için ilgili sorular; eşdeğer sözleşmelerin karşılaştırması değildir.
Will the FDA approve MDMA for PTSD?
KalshiWill the FDA approve intismeran autogene (V940/mRNA-4157)?
KalshiWhen will the FDA approve Intellia Therapeutics' lonvo-z?
KalshiWill the FDA approve any psychedelic substance for medical use this year?
KalshiWhen will the FDA approve Compass Pathways' COMP360 Psilocybin?
KalshiWill the FDA approve retatrutide?
KalshiKurallar
If the FDA approves CagriSema for marketing before Jan 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
Uzlaşma kaynağı:Food and Drug Administration
Her sonucun kuralı
- Before Jul 1, 2027
- If the FDA approves CagriSema for marketing before Jul 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2028
- If the FDA approves CagriSema for marketing before Jan 1, 2028, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Jan 1, 2027
- If the FDA approves CagriSema for marketing before Jan 1, 2027, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
- Before Oct 1, 2026
- If the FDA approves CagriSema for marketing before Oct 1, 2026, then the market resolves to Yes. An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application The following constitute approvals that trigger the Payout Criterion: Standard approval (traditional approval based on clinical benefit) Accelerated approval (based on surrogate endpoints) Approval with Risk Evaluation and Mitigation Strategy (REMS) Approval…
